Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

Company Overview

Codexis, Inc. (Nasdaq: CDXS) is a leading enzyme engineering company leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis, and the Company is currently developing its proprietary ECO Synthesis™ platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications.

Stock Snapshot

IR Contacts

Media Relations

Codexis, Inc.
200 Penobscot Drive
Redwood City, CA 94063
United States
T: 650-421-8205
Lauren Musto
media@codexis.com

Investor Relations

Codexis, Inc.
200 Penobscot Drive
Redwood City, CA 94063
United States
T: 650-421-8399
Carrie McKim
ir@codexis.com

Transfer Agent

EQ Shareowner Services
1110 Centre Pointe Curve
Suite 101
Mendota Heights, MN 55120-4100
T: 800-468-9716
https://www.shareowneronline.com